芪苈强心胶囊对老年慢性心力衰竭患者N末端脑钠肽前体、左心室射血分数、Tei指数的影响

目的观察芪苈强心胶囊对老年慢性心力衰竭(chronic heart failure，CHF)患者临床疗效、N末端脑钠肽前体(N-terminal pro-brain natriuretic peptide，NT-proBNP)、左心室射血分数(left ventricular ejection fraction，LVEF)、Tei指数的影响。 方法选择2014年6月至2015年7月在云南省第二人民医院门诊及住院部医治的170例老年CHF患者，采用数字表法随机分为2组，对照组85例，给予标准心力衰竭治疗；治疗组85例，在对照组治疗基础上加服芪苈强心胶囊(4粒，每日3次)。疗程均为3个月。观察并比较2组患者治疗前后临床疗效以及NT-proBNP水平、左心室舒张末期内径(left ventricular end-diastolic diameter，LVEDD)、LVEF、Tei指数的变化。 结果治疗3个月后，治疗组临床疗效明显优于对照组(88.1%比63.4%，P<0.05)。2组患者治疗后NT-proBNP水平下降，治疗组优于对照组(P<0.05)。2组患者LVEDD、Tei指数均降低(P<0.05)，LVEF增加(P<0.05)，治疗组上述指标改善均优于对照组(P<0.05)。2组均未发现明显不良反应。 结论芪苈强心胶囊能在标准心力衰竭基础上进一步降低NT-proBNP、LVEDD、Tei指数，提高LVEF，改善老年CHF患者心功能，且安全性好。

Effect of Qiliqiangxin capsule on NT-proBNP,LVEF and Tei index in elder patients with chronic heart failure

ObjectiveTo investigate the effect of Qiliqiangxin capsule on clinical efficacy, N-terminal pro-brain natriuretic peptide(NT-proBNP), left ventricular ejection fraction(LVEF)and Tei index in elder patients with chronic heart failure(CHF). MethodsA total of 170 elder patients with CHF were collected from June 2014 to July 2015 in the clinic of Yunnan Second People′s Hospital.All the patients were randomly divided into two groups by random number table method.In the control group, 85 patients were treated with standard treatment for heart failure.In the treatment group, 85 patients were given Qiliqangxin capusule additionally(4 granules, 3 times daily). The course of treatment was 3 months.The clinical efficacy, NT-proBNP, left ventricular end-diastolic diameter(LVEDD), LVEF and Tei index of both groups were observed and compared before and after treatment. ResultsAfter 3 months of treatment, clinical efficacy of the treatment group was significantly higher than that in the control group(88.1% vs.63.4%, P<0.05). In both groups, NT-proBNP levels, LVEDD and Tei index were significantly reduced after treatment(P<0.05), and LVEF was significantly increased(P<0.05). In addition, the improvements of the above indicators in the treatment group were better than those in the control group(P<0.05). Side effects were neither found in the two groups. ConclusionQiliqiangxin capsule can further reduce the level of NT-proBNP, LVEDD and Tei index, increase LVEF, and improve the cardiac function in elder CHF patients who received standard heart failure treatment with good safety.